| Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result |
FRIENDSWOOD, Texas, May 09, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from the first independent validation of the recently published Collaborative Ocular Oncology Group Study No. 2 (COOG2.1) by Harbour et al.1 The data, from a real-world cohort of 1,297 patients with uveal melanoma (UM), was presented at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting in Salt Lake City. |
globenewswire.com |
2025-05-09 11:00:00 |
Czytaj oryginał (ang.) |
| Castle Biosciences Celebrates Skin Cancer Awareness Month |
Castle continues its ongoing patient advocacy partnerships and highlights cancer journey to drive education and awareness for Skin Cancer Awareness Month |
globenewswire.com |
2025-05-07 11:00:00 |
Czytaj oryginał (ang.) |
| Castle Biosciences, Inc. (CSTL) Q1 2025 Earnings Call Transcript |
Castle Biosciences, Inc. (NASDAQ:CSTL ) Q1 2025 Earnings Conference Call May 5, 2025 4:30 PM ET Company Participants Camilla Zuckero - Vice President of Investor Relations and Corporate Affairs Derek Maetzold - Founder, President & Chief Executive Officer Matthew Goldberg - Senior Vice President, Medical Frank Stokes - Chief Financial Officer Conference Call Participants Sung Ji Nam - Scotiabank Kyle Mikson - Canaccord Puneet Souda - Leerink Partners Tom Peterson - Baird Paul Knight - KeyBanc Capital Markets Subbu Nambi - Guggenheim Mason Carrico - Stephens Thomas Flaten - Lake Street Mark Massaro - BTIG Operator Good afternoon and welcome to Castle Biosciences First Quarter 2025 Conference Call. As a reminder, today's call is being recorded. |
seekingalpha.com |
2025-05-06 02:58:07 |
Czytaj oryginał (ang.) |
| Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates |
Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.09 per share a year ago. |
zacks.com |
2025-05-05 22:20:46 |
Czytaj oryginał (ang.) |
| Castle Biosciences Reports First Quarter 2025 Results |
Q 1 2025 revenue increased 21% over Q 1 2024 to $88 million Q 1 2025 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, DecisionDx ® -SCC, TissueCypher ® ) increased 33% over Q 1 2024 Raising full-year 2025 revenue guidance to $287-297 million from $280-295 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, May 05, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the first quarter ended March 31, 2025. |
globenewswire.com |
2025-05-05 20:06:00 |
Czytaj oryginał (ang.) |
| Castle Biosciences to Acquire Previse |
Expected to complement Castle's current gastroenterology franchise Adds methylation technology developed at the Johns Hopkins University School of Medicine and additional technologies in development FRIENDSWOOD, Texas, May 05, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced it has signed a definitive agreement to acquire Capsulomics, Inc., d/b/a Previse. Previse is a gastrointestinal health company with a primary focus on chronic acid reflux related diseases, including esophageal cancer. |
globenewswire.com |
2025-05-05 20:05:00 |
Czytaj oryginał (ang.) |
| New Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer |
Additionally, an expert physician panel convened by EndoscopyNow will host a product theater on Sunday, May 4, at 2:45 p.m. Pacific Time, titled, “The Time is Now: A Clinical Practice Model to Help Prevent Progression from Barrett's to EAC” FRIENDSWOOD, Texas, May 02, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share new data on its TissueCypher Barrett's Esophagus test via two posters at the Digestive Disease Week® (DDW 2025) Annual Meeting, being held May 3-6 in San Diego. |
globenewswire.com |
2025-05-02 20:30:00 |
Czytaj oryginał (ang.) |
| New Study Shows Castle Biosciences' DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity |
Patients identified as low risk by DecisionDx-Melanoma had a 2.8% sentinel lymph node (SLN) positivity rate, well below the National Comprehensive Cancer Network® (NCCN) guidelines' 5% threshold to forgo sentinel lymph node biopsy (SLNB) surgery FRIENDSWOOD, Texas, April 30, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a new study in Cancer Diagnosis & Prognosis demonstrating that DecisionDx-Melanoma outperforms both American Joint Committee on Cancer (AJCC) staging and the CP-GEP test (clinicopathological and gene expression profiling model) in identifying patients at low risk of SLN positivity who may consider forgoing SLNB surgery.1 “When relying on genomic testing to guide critical decisions about procedures like SLNB, a test must demonstrate exceptional accuracy in identifying patients with minimal risk of metastasis," said Peter A. Prieto, M.D. |
globenewswire.com |
2025-04-30 21:00:00 |
Czytaj oryginał (ang.) |
| DecisionDx®-Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed with Cutaneous Melanoma |
FRIENDSWOOD, Texas, April 28, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its achievement of surpassing a significant milestone of 200,000 DecisionDx-Melanoma clinical test orders. DecisionDx-Melanoma is a 31-gene expression profile test that provides comprehensive, personalized results designed to improve risk-aligned management decisions for patients with stage I-III cutaneous melanoma. |
globenewswire.com |
2025-04-28 11:00:00 |
Czytaj oryginał (ang.) |
| New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis |
FRIENDSWOOD, Texas, April 25, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share new research intended to improve the care of patients with cutaneous and uveal melanoma (CM and UM, respectively) via poster presentations at the American Association for Cancer Research® (AACR) Annual Meeting 2025, being held April 25-30 in Chicago. "At Castle Biosciences, our commitment to advancing care for melanoma patients helps drive our continuous innovation," said Rebecca Critchley-Thorne, Ph.D. |
globenewswire.com |
2025-04-25 20:15:00 |
Czytaj oryginał (ang.) |
| Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships |
FRIENDSWOOD, Texas, April 08, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, is supporting key educational programs and initiatives throughout the month of April in recognition of Esophageal Cancer Awareness Month. The Company is proudly collaborating with the Esophageal Cancer Action Network (ECAN), the American Foregut Society (AFS) and The Gut Doctor PodcastLLC to promote esophageal cancer prevention, education and advocacy. |
globenewswire.com |
2025-04-08 11:00:00 |
Czytaj oryginał (ang.) |
| Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year |
FRIENDSWOOD, Texas, April 07, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has received a Top Workplaces USA Award for the fourth consecutive year. The national award program by Energage and USA Today celebrates organizations with 150 or more employees that have built exceptional workplace cultures. |
globenewswire.com |
2025-04-07 11:00:00 |
Czytaj oryginał (ang.) |
| Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences' DecisionDx®-Melanoma Test |
Consistent with prior studies, published results from Castle's DECIDE study show DecisionDx-Melanoma can both accurately identify patients with less than 5% risk of sentinel lymph node (SLN) positivity, who can safely consider forgoing the sentinel lymph node biopsy (SLNB) surgical procedure, and who are also unlikely to experience disease progression 1,2 As of the last follow-up, all of the patients in the third study analysis with a low-risk DecisionDx-Melanoma test result (Class 1A) were recurrence free, regardless of SLN status 3 FRIENDSWOOD, Texas, April 03, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the recent publication of two papers in the World Journal of Surgical Oncology and Cancer Medicine sharing reports from the prospective, multicenter DECIDE study demonstrating the significant impact of the Company's DecisionDx-Melanoma test on SLNB decision-making for patients with melanoma.3,4 SLNB is a surgical procedure commonly used to determine whether a patient's melanoma has spread to nearby lymph nodes. While useful in the prognosis of patients for whom cancer is found in the lymph nodes, SLNB returns a surgical result that is negative for metastasis in approximately 88% of patients who undergo the procedure.5 Current National Comprehensive Cancer Network® (NCCN) guidelines suggest forgoing SLNB when the likelihood of finding a positive SLN is less than 5%, considering SLNB when the risk is between 5-10% and offering the surgery when the likelihood of positivity is above 10%. |
globenewswire.com |
2025-04-03 11:00:00 |
Czytaj oryginał (ang.) |
| Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma |
Castle will present data on DecisionDx-Melanoma at the 11th World Congress of Melanoma and 21st European Association of Dermato-Oncology (EADO) Congress. |
globenewswire.com |
2025-04-01 20:30:00 |
Czytaj oryginał (ang.) |
| Castle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups |
New, combined validation cohort of 1,412 patients with high-risk squamous cell carcinoma (SCC) demonstrates that the addition of DecisionDx-SCC to Brigham & Women's Hospital (BWH) staging significantly refines metastatic risk prediction in patients classified as High-Risk and Very High-Risk by National Comprehensive Cancer Network (NCCN) guidelines to support improved, risk-aligned treatment pathway decisions Castle will also present new data showing DecisionDx®-Melanoma as a significant predictor of mortality in a real-world cohort of nearly 7,000 patients with early-stage cutaneous melanoma (CM), reinforcing its value in identifying patients who may benefit from treatment plan strategies to improve outcomes FRIENDSWOOD, Texas, March 28, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share new data on its risk-stratification tests for patients with skin cancers, DecisionDx-SCC and DecisionDx-Melanoma, via two poster presentations at the NCCN 2025 Annual Conference, being held March 28-30 in Orlando, Florida. As a top five, blue-ribbon abstract at the conference, Castle's poster on DecisionDx-SCC will also be shared in a special oral presentation with the other top-scoring submissions. |
globenewswire.com |
2025-03-28 18:15:00 |
Czytaj oryginał (ang.) |
| New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology Portfolio |
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will share new data on its DecisionDx-Melanoma and DecisionDx-SCC tests for patients with skin cancers at the 2025 AAD Annual Meeting. |
businesswire.com |
2025-03-07 09:00:00 |
Czytaj oryginał (ang.) |
| Castle Biosciences, Inc. (CSTL) Q4 2024 Earnings Call Transcript |
Castle Biosciences, Inc. (NASDAQ:CSTL ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Camilla Zuckero - VP, IR and Corporate Affairs Derek Maetzold - Founder, President and CEO Frank Stokes - CFO Conference Call Participants Subbu Nambi - Guggenheim Sung Ji Nam - Scotiabank Thomas Flaten - Lake Street Paul Knight - KeyBanc Mason Carrico - Stephens Tom Peterson - Baird Vidyun Bais - BTIG Kyle Mikson - Canaccord Operator Good afternoon, and welcome to Castle Biosciences Fourth Quarter and Full Year 2024 Conference Call. As a reminder, today's call is being recorded. |
seekingalpha.com |
2025-02-28 00:09:04 |
Czytaj oryginał (ang.) |
| Castle Biosciences, Inc. (CSTL) Surpasses Q4 Earnings and Revenue Estimates |
Castle Biosciences, Inc. (CSTL) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to loss of $0.10 per share a year ago. |
zacks.com |
2025-02-27 21:15:27 |
Czytaj oryginał (ang.) |
| Castle Biosciences Reports Fourth Quarter and Full-Year 2024 Results |
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #diagnostics--Castle Biosciences, Inc. (Nasdaq: CSTL), today announced its financial results for the fourth quarter and year ended December 31, 2024. |
businesswire.com |
2025-02-27 18:05:00 |
Czytaj oryginał (ang.) |
| Castle Biosciences to Participate in Upcoming Investor Conferences |
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences' executive management is scheduled to present a company overview at two investor conferences next month. |
businesswire.com |
2025-02-25 18:30:00 |
Czytaj oryginał (ang.) |
| CSTL Gears Up to Report Q4 Earnings: Here's What You Should Know |
Castle Biosciences' fourth-quarter 2024 earnings are likely to have gained from higher test volume growth of its dermatologic and non-dermatologic tests. |
zacks.com |
2025-02-24 14:45:28 |
Czytaj oryginał (ang.) |
| Castle Biosciences, Inc. (CSTL) Reports Next Week: Wall Street Expects Earnings Growth |
Castle Biosciences (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-02-20 13:05:41 |
Czytaj oryginał (ang.) |
| Wall Street Analysts See a 50.79% Upside in Castle Biosciences (CSTL): Can the Stock Really Move This High? |
The average of price targets set by Wall Street analysts indicates a potential upside of 50.8% in Castle Biosciences (CSTL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2025-02-20 12:55:28 |
Czytaj oryginał (ang.) |
| Castle Biosciences to Share Data Reinforcing the Clinical Value of Its Dermatologic Portfolio of Gene Expression Profile Tests at the 22nd Annual Winter Clinical Dermatology Conference - Hawaii® |
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle will share data supporting its dermatologic portfolio of GEP tests at the 2025 Winter Clinical Dermatology Conference - Hawaii, Feb. 14-19. |
businesswire.com |
2025-02-12 18:30:00 |
Czytaj oryginał (ang.) |
| Surging Earnings Estimates Signal Upside for Castle Biosciences (CSTL) Stock |
Castle Biosciences (CSTL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions. |
zacks.com |
2025-02-12 15:20:31 |
Czytaj oryginał (ang.) |
| Castle Biosciences (CSTL) Upgraded to Buy: Here's Why |
Castle Biosciences (CSTL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2025-02-12 15:01:13 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Think Castle Biosciences (CSTL) Could Surge 51.52%: Read This Before Placing a Bet |
The mean of analysts' price targets for Castle Biosciences (CSTL) points to a 51.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2025-01-29 12:55:21 |
Czytaj oryginał (ang.) |
| 4 Top-Ranked Stocks With Solid Net Profit Margins to Buy Now |
Buy these four top-ranked stocks, CSTL, OPFI, GCT and QIFU, with solid net profit margins to enhance your portfolio returns. |
zacks.com |
2025-01-22 11:10:27 |
Czytaj oryginał (ang.) |
| Castle's Poster on DecisionDx®-SCC Selected as a “Late Breakers” Top Five Finalist for the Akamai Award, Recognizing the Best Posters at Maui Derm Hawaii 2025 |
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle will share data supporting its dermatologic portfolio of tests for skin cancer through poster presentations at the Maui Derm Hawaii meeting. |
businesswire.com |
2025-01-17 09:00:00 |
Czytaj oryginał (ang.) |
| Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Results |
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced certain unaudited preliminary performance results for the fourth quarter and year ended Dec. 31, 2024. “Our strong fourth quarter performance underscores continued momentum built throughout 2024, reflecting the strength of our growth initiatives and the dedication of our team,” said Derek Maetzold, president and chief executiv. |
businesswire.com |
2025-01-12 20:00:00 |
Czytaj oryginał (ang.) |
| Castle Biosciences Announces New York State Department of Health Approval of Its TissueCypher® Barrett's Esophagus Test |
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #Barrettsesophagus--Castle Biosciences has received assay approval from the New York State Department of Health (NYSDOH) for its TissueCypher Barrett's Esophagus test. |
businesswire.com |
2025-01-06 09:00:00 |
Czytaj oryginał (ang.) |
| Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term |
These five geonomics and synthetic biology stocks are likely to soar in the short-term. They Are: CRSP, IMCR, GLUE, RIGL, CSTL. |
zacks.com |
2024-12-23 10:50:17 |
Czytaj oryginał (ang.) |
| Castle Biosciences Highlights Progress for its Pipeline Atopic Dermatitis Gene Expression Profile Test |
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle today provided an update on its test currently in development for use in patients diagnosed with moderate-to-severe atopic dermatitis. |
businesswire.com |
2024-12-23 09:00:00 |
Czytaj oryginał (ang.) |
| Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle's Compensation Committee of its Board of Directors granted restricted stock units (RSUs) as inducement material to new employees. |
businesswire.com |
2024-12-19 09:00:00 |
Czytaj oryginał (ang.) |
| 4 Solid Net Profit Margin Stocks to Boost Portfolio Returns |
Here, we present four stocks, CSTL, QFIN, ESEA and STRA, with solid net profit margins that can contribute toward making a strong portfolio. |
zacks.com |
2024-12-17 10:01:12 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Believe Castle Biosciences (CSTL) Could Rally 42.02%: Here's is How to Trade |
The average of price targets set by Wall Street analysts indicates a potential upside of 42% in Castle Biosciences (CSTL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2024-12-16 12:57:31 |
Czytaj oryginał (ang.) |
| Small Caps Are Winners of 2024: 5 Picks With Solid Short-Term Upside |
These five small cap stocks have strong growth potential for 2025. These are: TALK, RYAM, CSTL, PBAM, RSSS. |
zacks.com |
2024-11-28 10:50:27 |
Czytaj oryginał (ang.) |
| Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference |
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle's executive management will present a company overview at the Piper Sandler 36th Annual Healthcare Conference on Dec. 4, 2024, at 10:50 am ET. |
businesswire.com |
2024-11-20 09:00:00 |
Czytaj oryginał (ang.) |
| Castle Biosciences (CSTL) Is a Great Choice for 'Trend' Investors, Here's Why |
If you are looking for stocks that are well positioned to maintain their recent uptrend, Castle Biosciences (CSTL) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen. |
zacks.com |
2024-11-08 11:56:11 |
Czytaj oryginał (ang.) |
| Castle Biosciences to Present New Data Highlighting the Clinical Performance of DecisionDx®-Melanoma and MyPath® Melanoma at the American Society of Dermatopathology 61st Annual Meeting |
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ASDP24--Castle will share new data highlighting the clinical performance of its DecisionDx-Melanoma and MyPath Melanoma tests at the ASDP 61st Annual Meeting. |
businesswire.com |
2024-11-08 09:00:00 |
Czytaj oryginał (ang.) |
| Castle Biosciences (CSTL) Upgraded to Strong Buy: Here's Why |
Castle Biosciences (CSTL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). |
zacks.com |
2024-11-07 15:00:44 |
Czytaj oryginał (ang.) |
| Castle Biosciences, Inc. (CSTL) Q3 2024 Earnings Call Transcript |
Castle Biosciences, Inc. (NASDAQ:CSTL ) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Camilla Zuckero - VP, IR and Corporate Affairs Derek Maetzold - Founder, President and CEO Frank Stokes - CFO Conference Call Participants Kyle Mikson - Canaccord Genuity Corey Rosenbaum - Scotiabank Thomas Flaten - Lake Street Mason Carrico - Stevens Puneet Souda - Leerink Partners Paul Knight - KeyBanc Operator Good afternoon, and welcome to Castle Biosciences Third Quarter 2024 Conference Call. As a reminder, today's call is being recorded. |
seekingalpha.com |
2024-11-04 21:33:26 |
Czytaj oryginał (ang.) |
| Castle Biosciences, Inc. (CSTL) Tops Q3 Earnings and Revenue Estimates |
Castle Biosciences, Inc. (CSTL) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of a loss of $0.06 per share. This compares to loss of $0.26 per share a year ago. |
zacks.com |
2024-11-04 20:56:29 |
Czytaj oryginał (ang.) |
| Castle Biosciences, Inc. (CSTL) Hit a 52 Week High, Can the Run Continue? |
Castle Biosciences (CSTL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. |
zacks.com |
2024-11-01 12:16:11 |
Czytaj oryginał (ang.) |
| Castle Biosciences Presents Award-Winning Abstract at ACG 2024 Demonstrating Ability of Its TissueCypher® Test to Significantly Reduce Healthcare Costs Associated with the Management of Barrett's Esophagus Patients |
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ACG2024--New data at ACG 2024 demonstrates ability of TissueCypher to significantly reduce healthcare costs associated with management of Barrett's esophagus. |
businesswire.com |
2024-10-29 18:30:00 |
Czytaj oryginał (ang.) |
| Castle Biosciences to Participate in Upcoming Investor Conferences |
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle announces that its executive management is scheduled to present a company overview at three investor conferences in November. |
businesswire.com |
2024-10-28 09:00:00 |
Czytaj oryginał (ang.) |
| Here's Why Momentum in Castle Biosciences (CSTL) Should Keep going |
Castle Biosciences (CSTL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen. |
zacks.com |
2024-10-23 13:51:10 |
Czytaj oryginał (ang.) |
| Castle Biosciences, Inc. (CSTL) is a Great Momentum Stock: Should You Buy? |
Does Castle Biosciences, Inc. (CSTL) have what it takes to be a top stock pick for momentum investors? Let's find out. |
zacks.com |
2024-10-22 17:06:23 |
Czytaj oryginał (ang.) |
| Castle Biosciences Presents New Data at ASDS from Prospective, Multicenter CONNECTION Study Supporting Use of DecisionDx®-Melanoma to Guide SLNB Decisions in T1a Tumors with High-Risk Features and T1b Tumors |
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ASDS--Castle will share new data at ASDS supporting the clinical utility of its DecisionDx-Melanoma and DecisionDx-SCC tests. |
businesswire.com |
2024-10-20 09:00:00 |
Czytaj oryginał (ang.) |
| Recent Publications Affirm the Value of Gene Expression Profile Testing in Guiding a Definitive Diagnosis and Clinical Decision-Making in Melanocytic Lesions of Uncertain Malignant Potential |
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced the publication of two recent studies that provide further support for the clinical need of its MyPath® Melanoma GEP test. |
businesswire.com |
2024-10-16 11:00:00 |
Czytaj oryginał (ang.) |
| Castle Biosciences, Inc. (CSTL) Soars to 52-Week High, Time to Cash Out? |
Castle Biosciences (CSTL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. |
zacks.com |
2024-10-15 14:22:21 |
Czytaj oryginał (ang.) |